'Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors': Erratum

Abstract

Reports an error in the original article by S. Kasper et al (Human Psychopharmacology , 1994[Jan–Feb], Vol 9[1], 1–22). A clearer copy is provided of Figure 2, which displays the antidepressant efficacy of fluvoxamine, imipramine, and placebo in various severities of depression. (The following abstract of this article originally appeared in PA, Vol 81:38486.) This review deals with the safety and antidepressant efficacy of selective serotonin re-uptake inhibitors (SSRIs) At present, 5 SSRIs are used therapeutically in European counties (fluvoxamine, fluoxetine, paroxetine, sertraline, and citalopram). The antidepressant efficacy of these drugs has been tested both vs placebo and vs reference antidepressants (amitriptyline, imipramine), revealing comparable antidepressant efficacy to the active compounds and a significant superiority compared with placebo. Available studies provide initial evidence that SSRIs have good antidepressant efficacy in severe depression and suggest that they might lead to a faster decline of suicidal tendencies within major depression. Since they have a favorable side-effects profile in sum, compared with tri- and tetracyclic antidepressants, they can be recommended from the aspect of a 'side-effects-derived indication.' (PsycINFO Database Record (c) 2016 APA, all rights reserved)

Accession Number: 1995-02843-001. Partial author list: First Author & Affiliation: Kasper, S.; U Vienna, Psychiatric Dept, Austria. Release Date: 19950101. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Erratum/Correction. Language: English. Major Descriptor: Drug Therapy; Major Depression; Serotonin; Side Effects (Drug). Minor Descriptor: Fluoxetine; Fluvoxamine; Paroxetine. Classification: Clinical Psychopharmacology (3340). Population: Human (10). Page Count: 1. Issue Publication Date: May-Jun, 1994.